In prostate cancer theranostics, Lesniak et al. developed a PSMA-targeted dual-modal imaging platform using fourth-generation PAMAM dendrimers, capable of fluorescence and photoacoustic imaging. The gene discussed is FOLH1; the disease is Familial prostate cancer.